You are here

Award Data

For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 205021 - 205030 of 207727 results
  1. High Performance Energetic Propellant Ingredient Process Research and Development


    CL-20 is the most powerful conventional explosive known, but its high cost has limited its adoption in a range of potential applications. Par of the challenge in making these materials is the complexity of the reaction used to prepare the polycyclic cage. The complexity of this reaction makes it difficult to have insight into the reaction and to improve it. Additionally, several of the intermediat ...

    STTR Phase II 2018 Department of DefenseNavy
  2. Improving marginal allograft outcomes through cell junction stabilization in transplantation

    SBC: FirstString Research, Inc            Topic: 400

    Project Summary/Abstract: Transplantation is a highly successful therapy for end-stage renal disease but there is a significant shortage of available donor organs that has forced utilization of low-quality kidneys to save patient’s lives. Extending the donor criteria has coincided with a growing appreciate that factors associated with organ donation, procurement and storage greatly affect post-t ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Advanced Solid Rocket Motor Technology for Tactical Missiles


    ABSTRACT:Knobley Technical Associates Phase Il Advanced Solid Rocket Motor Technologies for Tactical Missiles program includes design, analysis, development and testing efforts to define and mitigate technical and operational challengesto be investigated and resolved for successful maturation ofthe performance enhancing burn-rate augment highly loaded propellant grain technology for next generatio ...

    SBIR Phase II 2015 Department of DefenseAir Force
  4. Real-time Multimedia Communications in Highly Mobile Networks.

    SBC: Sensintel Inc.            Topic: N/A

    Based on the success demonstrated in the Phase I programs, this Phase II program will transition AINS technology developed in the universities into various compelling demonstrations that demonstrate the robust advantages of AINS. In the four Phase Iprograms we were able to perform significant initial AINS technology

    STTR Phase II 2003 Department of DefenseNavy
  5. Dramatic Improvement In The Quantum Efficiency Of Large-Format Longwave Infrared Focal Plane Arrays for THAAD Sensor Upgrade

    SBC: QMAGIQ LLC            Topic: MDA05009

    MDA is considering several technologies to upgrade the THAAD sensor. QWIP (Quantum Well Infrared Photodetector) technology is one option being considered. While QWIP has clear advantages (e.g. large formats, high pixel operability, excellent uniformity and image stability, low cost, and proven multi-color capability), its quantum efficiencies have to be improved (to > 40% internal QE, > 15-20% e ...

    SBIR Phase II 2007 Department of DefenseMissile Defense Agency
  6. An epitope-focused nanoparticle vaccine for anthrax

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    Abstract We have successfully developed a highly immunogenic, optimized and lyophilizable epitope-focused, bivalent anthrax vaccine, referred to as LND-LF-VLP, using our novel proprietary platform technology which incorporates the vaccine target sequence into highly immunogenic virus like particles. This new vaccine targets two distinct neutralizing determinants, which are not targeted by Biothrax ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health

    SBC: AJ MEDICAL DEVICES, INC.            Topic: N/A

    It is estimated that 220,000 people suffer cardiac arrest each year in the US, of whom only 10,000 survive to hospital discharge. The number of survivors could increase 10-fold if paramedical attention and/or defibrillation were available within a few min

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Phase 1 cross over biodistribution study of [203Pb]VMT01 for single photon emission computed tomography (SPECT) and [68Ga]VMT02 for positron emission tomography (PET) imaging of stage 4 melanoma


    SIGNIFICANCE: Melanoma incidence is rising faster than any other cancer and metastatic melanoma is typically fatal. Responses to targeted and immunotherapies can be remarkable, but low response rates, acquired resistance, and adverse side effects limit long-term quality of life for these patients. The overall response rate to all therapies remains dismally near 50% and the 5-year survival is andlt ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Genital Herpes Vaccine Discovery

    SBC: MOLECULAR EXPRESS, INC            Topic: N/A

    DESCRIPTION (provided by applicant): The primary objective of this project is to develop, using a novel vaccine platform technology (the VesiVax(r) system), a safe HSV2 vaccine that is capable of providing a level of protection in male and female human pop ulations which is better than other recombinant vaccines. We have shown that HSV2 VesiVax(r) vaccines targeted to single epitopes from the gD e ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  10. PathMAP NSCLC: A functional companion diagnostic test to predict optimal therapy for patients with non-small cell lung cancer.

    SBC: Biomarker Strategies, LLC            Topic: 102

    Lung cancerLCis the leading cause of cancer death in the US with an estimateddeaths inNonsmall cell LC is the predominant category of the diseaseNSCLCMolecular characterization of tumors has shifted the paradigm of one drug fits allCurrentlymolecularly targeted agentsMTAsand companion diagnosticsCDxare being developed to target oncogenic drivers in signaling pathwaysand select patients most likely ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government